- Home
- NRXS vs ASRT Comparison
NRXS vs ASRT Comparison
Compare NRXS & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | ASRT |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.9M | 76.0M |
| IPO Year | 2023 | 2004 |
Fundamental Metrics
Financial Performance| Metric | NRXS | ASRT |
|---|---|---|
| Price | $7.43 | $23.43 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $13.00 | ★ $18.00 |
| AVG Volume (30 Days) | 177.3K | ★ 421.1K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,569,282.00 | ★ $118,713,000.00 |
| Revenue This Year | $172.91 | N/A |
| Revenue Next Year | $115.71 | $12.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.89 | N/A |
| 52 Week Low | $2.20 | $0.60 |
| 52 Week High | $9.33 | $23.46 |
Technical Indicators
Market Signals| Indicator | NRXS | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 86.13 |
| Support Level | $6.80 | $0.70 |
| Resistance Level | $8.03 | N/A |
| Average True Range (ATR) | 0.63 | 0.18 |
| MACD | -0.16 | -0.03 |
| Stochastic Oscillator | 8.97 | 98.48 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.